Skip to main content
. 2020 Jul 20;38(3):291–299. doi: 10.1080/02813432.2020.1794409

Table 1.

Description of the study population and outcome by prescribed antibiotic.

Antibiotic Pivmecillinam Nitrofurantoin Trimethoprim SXTa Ciprofloxacin Total
n = 5234 n = 3223 n = 920 n = 791 n = 10956 n = 21 124
Age, years, median (IQR) 64 (49–72) 65 (49–72) 66 (53–73) 66 (56–72) 65 (53–72) 65 (51–72)
Level of care, index
Primary health care n (%) 4815 (92.0) 3014 (93.5) 756 (82.2) 406 (51.3) 8188 (74.7) 17179 (81.3)
Hospital care n (%) 419 (8.0) 209 (6.5) 164 (17.8) 385 (48.7) 2768 (25.3) 3945 (18.7)
Measurements
Median temperatureb Celsius (IQR) 36.9 (36.5–37.2) 36.9 (36.6–37.2) 36.8 (36.4–37.2) 37.5 (36.8–38.3) 37.0 (36.6–37.6) 37.2 (36.7–37.9)
CRP, mg/Lc median, (IQR) 7.0 (5.0–26.0) 7 (5–26.0) 11.0 (5.0–36.2) 41.0 (14.0–96.0) 40 (8.0–96.0) 24.0 (5–75)
Nitrite-positivedn(%) 796 (30) 400 (27) 111 (27) 130 (42) 1917 (39) 3354 (34)
Leukocytes posistiveen(%) 2310 (70) 1242 (67) 395 (76) 342 (78) 5124 (77) 9413 (74)
Urine culture analysed n (%) 2701 (52) 1613 (50) 512 (56) 503 (64) 6326 (58) 11 655 (55)
Duration of therapy
0-9 days
n (%)
4722 (90.4) 2839 (88.2) 677 (73.8) 357 (45.5) 5251 (48.0) 15073 (65.5)
10 days or more, n (%) 501 (9.6) 380 (11.8) 240 (26.2) 428 (54.1) 5679 (51.8) 7834 (34.1)
Median duration of therapy days (IQR) 7 (7–7) 5 (5–7) 7 (5–10) 10 (7–10) 10 (7–10) 7 (7–10)
Outcome
Therapy failure n (%) 63 (1.2) 40 (1.2) 11 (1.2) 11 (1.2) 69 (0.6) 192 (0.9)
Recurrence n (%) 496 (9.5) 283 (8.8) 61 (6.6) 61 (6.6) 384 (3.5) 1277(6.0)
Complication n (%) 25 (0.5) 20 (0.6) 4 (0.4) 4 (0.4) 61 (0.6) 121 (0.6)
a

SXT: Trimethoprim/sulfamethoxazole.

b

Missing cases for temperature, 13,242 (62.7%) of all index patients.

c

CRP (C-reactive protein), missing cases 12,345 (58.4%).

d

Measured by dipstick test in urine, missing cases 11,118 (53%).

e

Measured by dipstick test in urine, missing cases 9413 (46%).